Abstract: A method for treating polycystic kidney disease in an individual in need thereof. This method includes identifying a mammal having a cystic disease and administering to the mammal a pharmacologically effective anti-cystic amount of TNF-.alpha. or an agent which stimulates TNF-.alpha. production in vivo. The agent is administered in a pharmacologically acceptable carrier, excipient or diluent.

Abstract: Compositions for pain relieving non-steroidal anti-inflammatory drugs and/or medicaments such as ibuprofen, methotrexate, capsaicin, diphenhydramine, aspirin, methyl-nicotinate and other medicaments largely soluble in oil, alcohol, and/or water, are produced for transdermal delivery. The composition is manufactured by admixing an appropriate amount of oil surfactant with an appropriate amount of pharmaceutically approved co-solubilizer alcohol to establish a non aqueous phase. The oil surfactant may be a polyethoxylated oil such as castor oil. The co-solubilizer solubilizer may be isopropyl alcohol or virtually any other alcohols except for methanol. Thereafter, an appropriate amount of distilled water is slowly added to the homogeneous or non-aqueous phase to further reduce viscosity. The final admixture is a clear, oil-continuous solution having a viscosity no greater than 850 centistokes as measured by the VST Hoppler method at 25 degrees Celsius.

Abstract: The present invention concerns composition, kits and methods for reducing the flushing effect (cutaneous erythema) of an antilipemic drug, for treating hyperlipemia, for improving the effectiveness of an anti-platelet aggregating drug (e.g., in nonresponders) and for treating thrombosis. The present compositions and kits for reducing the flushing effect and for treating hyperlipemia contain an antilipemic drug (such as niacin) and either a sustained release NSAID (such as aspirin) or an NSAID and a carboxylic acid compound other than the NSAID and antilipemic drug. The kits contain (a) pre-dosages of the NSAID and optional carboxylic acid compound and (b) an antilipemic dosage of the antilipemic drug, which optionally may be combined with NSAID and optional carboxylic acid compound in an amount effective to maintain the reduction of the flushing effect.

Abstract: Disclosed herein is a method of treating pain caused by bursitis, tendinitis, arthritis, and the like, comprises ingesting an effective amount of a non-steroidal anti-inflammatory drug, and ingesting an effective amount of L-or DL-Methionine and a sugar which provides relief from stomach discomfort caused by the non-steroidal anti-inflammatory drug and which in combination with the non-steroidal anti-inflammatory drug results in relieving the pain more effectively than the non-steroidal anti-inflammatory drug alone.

Abstract: This invention provides a method of augmenting the therapeutic activity of an oxyalkylene-containing compound, butyric acid, a butyric acid salt or butyric acid derivative by administering an inhibitor of .beta.-oxidation of fatty acids to a patient or to host cells. Pharmaceutical compositions are also included.

Abstract: The administration of the PAF antagonists BN 52021 and SR 27417, in combination with cyclooxygenase antagonist indomethacin are disclosed as effective in inhibiting the secretory effects caused by Cholera toxin.

Abstract: The invention relates to the use of a non-steroidal anti-inflammatory drug together with an opioid analgesic in the manufacture of a medicament for the treatment of arthritis.

Abstract: Disclosed herein are methods for increasing the aqueous solubility and bio-availability of bioactive agents having a free carboxyl group by conjugating the agent to one or more amino alcohol phosphocholine moieties selected from the group consisting of sphingosylphosphocholine, 2-aminoglycerol phosphocholine, serine-phosphocholine, threonine phosphocholine, tyrosine-phosphocholine, aminoethanol-phosphocholine or hydroxyproline-phosphocholine. Also disclosed herein are pharmaceutical formulations comprising the agents produced by the method.

Abstract: A method of administering a medicinal agent and an effective amount of a form of hyaluronic acid for decreasing side effects associated with using the agent alone in treating a disease or condition in mammals is disclosed. The agent may be a non-steroidal anti-inflammatory drug (NSAID). The amount of hyaluronic acid is sufficient enough to provide a dosage greater than 200 mg/70 kg person. The molecular weight of the form of hyaluronic acid may be less than 750,000 daltons.

Abstract: The present invention provides therapeutic conjugates which comprise a therapeutic compound bound to one to three acyl groups derived from fatty acids. The therapeutic compounds are preferably non.about.steroidal anti.about.inflammatory agents which include a carboxylic acid group. The compounds involve the use of tromethamine or ethanolamine derivative to link the acyl groups derived from fatty acids to the therapeutic compounds.

Abstract: The present invention concerns methods for reducing cutaneous flushing in a patient to whom niacin is administered. According to the present method, two or more doses of a nonsteroidal anti-inflammatory drug are administered to a patient prior to administering niacin. Alternatively, the nonstcroidal anti-inflammatory drug can be administered concurrently with niacin administration. The nonstcroidal anti-inflammatory drug can be aspirin, ibuprofen, indomethacin, phenylbutazone, or naproxen. The nonsteroidal anti-inflammatory drug is administered in an amount effective to reduce cutaneous flushing caused by the niacin, and is administered in an amount up to 160 mg for aspirin and ibuprofen, 10 mg for indomethacin, and 100 mg for phenylbutazone and naproxen.

Abstract: The invention relates to the use of a non-steroidal anti-inflammatory drug together with an opioid analgesic in the manufacture of a medicament for the treatment of arthritis.

Abstract: The present invention relates to a new N-cinnamoyl-2-methyl-5-methoxy-3-indoleacetic ester represented by the following general formula (I). It is manufactured by causing N-cinnamoyl-2-methyl-5-metboxy-3-indoleacetic acid represented by the following general formula (II) or a reactive derivative thereof to react with a compound represented by the following general formula (III) ##STR1## wherein, R is ##STR2## The inventive compounds are effective to the same extent as the existing cinmetacin, and are also excellent in greatly reducing fatal side effects like a gastric ulcer, that are associated with cinmetacin or an intestinal ulcer.

Abstract: A novel method for preventing, stabilizing or causing regression of vascular leak syndrome is disclosed. The method comprises administering to a patient in need thereof a compound selected from the group consisting of a corticosteroid, a non-steroidal anti-inflammatory agent, 15-deoxyspergualin and related compounds, and phospholipase A.sub.2 inhibitors.

Abstract: The invention concerns the recognition that certain non-steroidal anti-inflammatory agents can overcome or ameliorate limitations on trabecular meshwork cell division produced by environmental stresses (e.g., oxidative or phagocytic injury, or glucocorticoid exposure), and thus can be used to prevent or treat loss of trabecular cells found in certain forms of glaucoma and in normal aging. The use of such non-steroidal anti-inflammatory agents can ameliorate the severity, or prevent glaucoma.

Abstract: This invention provides methods for treating or preventing a condition associated with an excess of neuropeptide Y which methods comprise administration of one or more substituted benzofurans, benzothiophenes or indoles.

Abstract: The present invention provides a method of diagnosing and treating a pregnant female at risk for impending preterm delivery. The method comprises the step of diagnosing imminent preterm delivery by testing with a method that has a sensitivity of at least 80% and a specificity of at least 80%, or by testing for fetal fibronectin in the female's vaginal or cervical secretions. If imminent preterm delivery is indicated by the test, the next step comprises administering to the female a combination of a tocolytic agent, at least one urinastatin-like compound, and at least one antibiotic. Also provided is a pharmaceutical composition of MGMTSRYFYNGTSMA (SEQ ID NO:1), RAFIQLWAFDAVKGK (SEQ ID NO:2) and an antibiotic.

Abstract: The present invention relates, in general, to a method of preventing or delaying the onset of Alzheimer's disease and related neurodegenerative disorders. The method involves the administration to individuals at risk of developing the disease (or disorder) a non-steroidal anti-inflammatory agent and/or a histamine H2 receptor blocking agent. The invention also relates to a method of treating Alzheimer's disease and related neurodegenerative disorders that involves the use of such agents.

Abstract: Formulations of programmed-release medicinal products intended for parenteral administration by injection, comprising calibrated solid microspheres (1 to 300 microns) of active substances. Provided in this form, steroids (for example progesterone and 17-.beta.-estradiol) may constitute injectable contraceptives, and the action of drugs having an approximatively 24 hours lasting effect may be regulated and extended.

Abstract: A percutaneous absorption promoting agent comprising (A) at least one anionic surfactant and one or two or more of surfactants having a nitrogen atom in the molecule other than anionic surfactants, (B) one or two or more of anionic surfactants and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, (C) one or two or more of surfactants selected from the group consisting of amphoteric surfactant and semi-polar surfactants and at least one nonionic surfactant having a nitrogen atom in the molecule, (D) one or two or more of surfactants selected from the group consisting of nonionic surfactants, amphoteric surfactants, semi-polar surfactants and cationic surfactants having a nitrogen atom in the molecule, and one or two or more of nonionic surfactants not having a nitrogen atom in the molecule, or (E) an amine oxide as the active ingredient, and a dermatological preparation containing these percutaneous absorption promoting agent and drug components.

Abstract: Catechol derivatives of the formula ##STR1## wherein Ra, Rb and Rc have the significance given herein, the ester and ether derivatives thereof which are hydrolyzable under physiological conditions and the pharmaceutically acceptable salts thereof are described and possess valuable pharmacological properties. In particular, they inhibit the enzyme catechol-O-methyltransferase (COMT), a soluble, magnesium-dependent enzyme which catalyses the transference of the methyl group of S-adenosylmethionine to a catechol substrate, whereby the corresponding methyl ethers are formed. Suitable substrates which can be O-methylated by COMT and which can thus be deactivated are, for example, extraneuronal catecholamines and exogeneously-administered therapeutically active substances having a catechol structure.

Abstract: The present invention relates to a drug composition in which the solubility and the dissolution rate of a drug having low water solubility are improved by incoroprating therein a low molecular weight chitosan in an amount of from 0.2 to 10 parts by weight per one part by weight of the poorly water-soluble drug. As the low molecular weight chitosan, those having a weight average molecular weight in the range from 500 to 50,000 and soluble in water were employed. This drug composition is prepared by mixing the components intimately so as to obtain a homogeneous dispersion of the low molecular weight chitosan with the mass of the composition.The drug composition according to the invention can be worked up into various preparation forms, such as, granules etc., as medicaments for administration to living organisms in which the bioabsorptivity and biouptake are improved.

Abstract: A pharmaceutical aqueous solution for ophthalmic use comprising a nonsteroidal anti-inflammatory drug, having a carboxylic group, a decongestant drug and a mixture of a polysorbate and a poloxamer.

Abstract: A method for treating mammals suffering from rheumatoid arthritis and other tissue-destructive (chronic inflammatory or other) conditions associated with excess metalloproteinase activity comprising administering to the mammal an amount of a tetracycline that is effectively anti-metalloproteinase, but that is not effectively antimicrobial, and an amount of non-steroidal anti-inflammatory agent which, when combined with the effectively anti-metalloproteinase amount of tetracycline, results in a significant reduction of tissue destruction and/or bone loss.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals and into the blood stream in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer.

Abstract: Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections.In addition, pharmaceutical preparations for topical administration are provided containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.

Abstract: Compounds of the structures shown below are specific inhibitors of cyclooxygenase-2 useful in the treatment of cyclooxygenase-2 mediated disease states such as inflammation, pain and fever, and are non-ulcerogenic.

Abstract: The invention relates to the treatment of antibiotic associated colitis, typically due to Clostridium difficile using the Platelet Activating Factor antagonists WEB 2170, SR 27417 or BN 52021, or the cyclooxygenase antagonist indomethacin. The PAF antagonists BN 52021 and SR 27417 and the cyclooxygenase antagonist indomethacin were effective in inhibiting the secretory effects caused by C. difficile Toxin A and by Cholera toxin.

Abstract: A process for the production of semisolid preparations containing micronized active ingredients is described which is characterized in that a mixture of one or two nonionic surfactants with an HLB of 9 to 18 with 2.3 to 100 times the amount by weight of a fatty acid ester of general formulaR.sub.1 --COO--R.sub.2in which R.sub.1 and R.sub.2 each represent alkyl groups or alkenyl groups with 12 to 32 carbon atoms, or a mixture of these fatty acid esters is heated until it melts, the melt with stirring is put into 10 to 200 times the amount by weight of a semisolid preparation, which is heated approximately to the same temperature, the mixture is allowed to cool with stirring and mixed with the micronized active ingredient or active ingredient mixture as well as optionally with scents.

Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.

Abstract: The present invention relates to an aqueous pharmaceutical suspension composition comprising: from about 0.2% to 20% of a substantially water insoluble pharmaceutical active, e.g. ibuprofen; a suspension stabilizing effective amount of xanthan gum, pregelatinized starch and polyoxyethylene sorbitan monooleate; an effective amount of taste masking composition; and water, as well as a process for producing such aqueous pharmaceutical suspensions.

Abstract: Methods for treating the cornea following UV laser irradiation and resulting photoablation of corneal tissue are disclosed. The methods include administration of compositions of a non-steroidal antiinflammatory to the eye. Compositions for use in treating the cornea are also disclosed.

Abstract: A method for increasing the proportion of a crystalline organic compound which remains amorphous and suppressing recrystallization in which a crystalline organic compound and a hydrophilic polymer substance are fixed onto a surface of core particles by means of impacts applied in a high velocity gas stream. The solubility and stability of the resulting composite product, such as a drug for internal use, can be improved.

Abstract: This application describes 3-arylalkyl esters of 4,5-dihydro-9,10-dioxo-2-anthracenecarboxylic acid and a process for making them. Also described is a method of using the compounds in the treatment of arthritis.

Abstract: A method for treating mammals suffering from rheumatoid arthritis and other tissue-destructive (chronic inflammatory or other) conditions associated with excess metalloproteinase activity comprising administering to the mammal an amount of a tetracycline that is effectively anti-metalloproteinase, but that is not effectively antimicrobial, and an amount of non-steroidal anti-inflammatory agent which, when combined with the effectively anti-metalloproteinase amount of tetracycline, results in a significant reduction of tissue destruction and/or bone loss.

Abstract: Compositions for pain relieving non-steroidal anti-inflammatory drugs and/or medicaments such as ibuprofen, methotrexate, capsaicin, diphenhydramine, aspirin, methylnicotinate and other medicaments largely soluble in oil, alcohol, and/or water, are produced for transdermal delivery. The composition is manufactured by admixing an appropriate amount of oil surfactant with an appropriate amount of pharmaceutically approved co-solubilizer alcohol to establish a non aqueous phase. The oil surfactant may be a polyethoxylated oil such as castor oil. The co-solubilizer may be isopropyl alcohol or virtually any other alcohols except for methanol. Thereafter, an appropriate amount of distilled water is slowly added to the homogeneous or non-aqueous phase to further reduce viscosity. The final admixture is a clear, oil-continuous solution having a viscosity no greater than 850 centistokes as measured by the VST Hoppler method at 25 degrees Celsius.

Abstract: Topically applied non-steroidal antiinflammatory agents (NSAID's) are useful in the treatment of macular degeneration.

Abstract: Disclosed are fluorocarbon emulsions comprising amino acids and substances related to amino acids, such as substituted amino acids or amphoteric groups of amino acid side chains, for example, the imidazolyl group of histidine. Emulsion formulations comprising imidazole and imidazole based drugs possess anti-inflammatory and antipyretic properties which counteract transient inflammatory responses which occur when these emulsions are administered in vivo. Lipid constituents of histidine-containing emulsions are protected against oxidation caused by free radical formation.Disclosed also are emulsion formulations buffered with amino acids comprising histidine, imidazole, and related compounds that have a buffering capacity sufficient to maintain the emulsion pH within a specified range under storage conditions and protect these emulsions from the endogenous production of acid.

Abstract: Methods for preventing and treating corneal haze resulting from exposure of the eye to laser irradiation are disclosed. The methods include administration of compositions of wound healing modulators to the eye. Compositions for use in preventing and treating the corneal haze are also disclosed.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals and into the blood stream in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer being a carboxylic acid derivative or a salt thereof represented in one embodiment by the general formula ##STR1## wherein W represents oxygen, sulfur, or two hydrogen radicals; wherein Z represents oxygen, sulfur, or --CH.sub.2 --;wherein R represents alkyl optionally substituted with one to three double or triple bonds, --SR'", --OR'", --NHR'", --CH.sub.3, or COOR.sub.1, and wherein R.sub.1 represents hydrogen or lower alkyl;wherein R'" represents alkyl, alkylthioalkyl, alkoxyalkyl, substituted aminoalkyl, optionally substituted with a phenyl, benzoyl or heterocyclic group;wherein R' represents hydrogen, alkyl, alkoxy, acyloxy, alkylthio, hydroxy, --(CH2).sub.

Abstract: A method of treating poultry suffering from leg bone joint infection and/or leg weakness by administering to the poultry an effective amount of a non-steroidal anti-inflammatory drug and composition of such drug.

Abstract: This invention relates to a method for administering systemically active agents including therapeutic agents through the skin or mucosal membranes of humans and animals in a transdermal device or formulation comprising topically administering with said systemic agent an effective amount of a membrane penetration enhancer having the structural formula ##STR1## wherein X is selected from the group consisting of oxygen and sulfur; R' is H or a lower alkyl group having 1-4 carbon atoms; m is 2-6; n is 0-17 and R is --CH.sub.3 ; wherein R is H or a lower alkyl group, m is 5-7 and n is 0-17.

Abstract: This invention relates to a pharmaceutical composition for treating the symptoms of overidulgence comprising an analgesic effective amount of acetaminophen or a non-steroidal anti-inflammatory drug and a gastric acid inhibiting effective amount of an H.sub.1 or H.sub.2 blocker, proton pump inhibitor or a combination thereof and methods of treating the symptoms of overindulgence comprising administering such pharmaceutical compositions.

Abstract: An external preparation is characterized by comprising calcium silicate. The calcium silicate controls the release rate and percutaneous absorbability of a drug.

Abstract: This invention pertains to the novel use of anti-rheumatoid arthritic drugs in the treatment of dementia. A method of treating dementia in human beings which comprises administering to the human being a therapeutic amount of a non-steroidal anti-inflammatory drug (NSAID) which has the ability to inhibit prostaglandin synthesis in the human being.

Abstract: Pharmaceutically elegant oral compositions of non-steroidal anti-inflammatory drugs or their salts are prepared by adding selected dispersing agents such as a polyvinylpyrrolidone, hydroxypropyl-methylcellulose or hydroxypropylcellulose to the NSAIDs in a medium of polyol-glycol-alcohol. The compositions offer the formation of finely dispersed active ingredients upon dispersion in gastric juice.

Abstract: Two pharmaceutically useful fractions of hyaluronic acid are obtained comprising a first fraction with a molecular weight between 50,000 and 100,000 which is useful for wound healing, and a second fraction having a molecular weight between 500,000 and 730,000 which is useful for intraocular and intraarticular injections.In addition, pharmaceutical preparations for topical administration are provided containing a pharmacologically active substance together with hyaluronic acid or a molecular weight fraction thereof. The hyaluronic acid may be in the form of the free acid or may be a salt with an alkali or alkaline earth metal, magnesium, aluminum or ammonium, or in the form of a salt with one or more pharmacologically active substances.

Abstract: A transdermal therapeutic formulation comprising d-limonene and at least one pharmaceutically active substance wherein the content of the d-limonene is in the range from 0.1 to 2 weight percent, based on the total amount of the formulation. The transdermal therapeutic formulation has an excellent percutaneous absorption, is safe and is capable of delivering desired pharmaceutically active substances to a desired location of treatment or to the entire body of a patient through the circulatory system and is thus effective for curing various diseases.

Abstract: The present invention relates to a process for solubilizing at least one difficultly soluble pharmaceutical active in a mixture of polyethylene glycol and polyvinylpyrrolidone. The process does not require water as a solvent or the use of a heating step. In further embodiments, the present invention also relates to a process for encapsulating these solubilized pharmaceutical compositions within soft gelatin shells, which are preferably transparent. Both the resulting compositions and their capsules provide an effective means for oral delivery of a wide variety of difficultly soluble pharmaceutical actives.

Abstract: Zinc acexamate acts by increasing the synthesis of mucus, reinforces the mucous barrier, improves the microcirculation and increases the synthesis of prostaglandins in the gastric mucous membrane, whereby it is effective in the treatment of said gastropathy, contrary to the results obtained with antiacids or antisecretory agents.